These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 7264627)

  • 1. Treatment of Parkinson's disease: problems with a progressing disease.
    Rinne UK
    J Neural Transm; 1981; 51(1-2):161-74. PubMed ID: 7264627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging.
    Rinne UK
    Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.
    Rinne UK
    Neurology; 1987 May; 37(5):826-8. PubMed ID: 3574685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK
    Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term responses of Parkinson's disease to levodopa therapy.
    Rinne UK; Sonninen V; Siirtola T; Marttila R
    J Neural Transm Suppl; 1980; (16):149-56. PubMed ID: 6776234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined bromocriptine-levodopa therapy early in Parkinson's disease.
    Rinne UK
    Neurology; 1985 Aug; 35(8):1196-8. PubMed ID: 4022354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R
    J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages.
    Ogawa N
    Eur Neurol; 1994; 34 Suppl 3():20-8. PubMed ID: 7821332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonists in Parkinson's disease.
    Calne DB; Burton K; Beckman J; Martin WR
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):221-4. PubMed ID: 6231979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Parkinson's disease with multiple drugs].
    Kuno S
    Nihon Rinsho; 1997 Jan; 55(1):59-64. PubMed ID: 9014424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problems associated with long-term levodopa treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():19-26. PubMed ID: 6587715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease.
    Laihinen A; Rinne UK; Suchy I
    Acta Neurol Scand; 1992 Dec; 86(6):593-5. PubMed ID: 1481646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.